Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.

Cancer chemotherapy and pharmacology - 1 Sept 2020

Elmeliegy Mohamed, Den Haese Jason, Talati Chetasi, Wetzler Meir, Jusko William J

Abstract excerpt

BACKGROUND: AML patients with FLT3/ITD mutations have poor response to cytarabine-based chemotherapy. FLT3 inhibitors (FLT3i) may resensitize cells to cytarabine (CYT). Improving treatment outcome of this combination may benefit from a mechanistic extrapolation approach from in vitro data. METHODS: The effects of CYT and several FLT3i on cell proliferation and cell cycle kinetics were examined in AML cell lines....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Biomarkers, Tumor
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Movement

Share to Gene Expression Regulation, Neoplastic

Share to Mutation

Share to Prognosis

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 32748108
DOI: 10.1007/s00280-020-04114-z
PMCID: PMC7539618

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.PMID 32748108Read ↗

Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITDSemantic proximity Read ↗

Management and risk mitigation strategies for FLT3-ITD+ acute myeloid leukemia: clinical utilization of quizartinib.Semantic proximity Read ↗

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.Semantic proximity Read ↗

Functionalist Oncology to Model the Contextuality of Dynamics and Treatment in Acute Myeloid LeukemiaSemantic proximity Read ↗

Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.Semantic proximity Read ↗

All-trans retinoic acid potentiates cell death induced by quizartinib in acute myeloid leukemia with FLT3-ITD mutations.Semantic proximity Read ↗

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.Semantic proximity Read ↗

Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.Semantic proximity Read ↗

Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II TrialSemantic proximity Read ↗

Computer simulations of the signalling network in FLT3 +-acute myeloid leukaemia - indications for an optimal dosage of inhibitors against FLT3 and CDK6.Semantic proximity Read ↗

Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells.Semantic proximity Read ↗

Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.